Paloxi ODT
Generic Name
Palonosetron
Manufacturer
Healthcare Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| paloxi odt 05 mg tablet | ৳ 22.00 | ৳ 220.00 |
Description
Overview of the medicine
Paloxi ODT contains Palonosetron, a selective 5-HT3 receptor antagonist used for the prevention of chemotherapy-induced nausea and vomiting (CINV). It is designed to dissolve rapidly in the mouth.
Uses & Indications
Dosage
Adults
0.25 mg orally once approximately 1 hour prior to the start of chemotherapy.
Elderly
No specific dosage adjustment is required for elderly patients.
Renal_impairment
No dosage adjustment is required for patients with mild to severe renal impairment. Palonosetron is not removed by hemodialysis.
How to Take
Place the Paloxi ODT on the tongue. It will rapidly disintegrate in saliva and can be swallowed with or without water. Do not chew or crush the tablet.
Mechanism of Action
Palonosetron selectively blocks serotonin, primarily at 5-HT3 receptor sites located on vagal nerve terminals in the gastrointestinal tract and in the chemoreceptor trigger zone (CTZ) of the central nervous system, thus preventing nausea and vomiting.
Pharmacokinetics
Onset
Onset of action typically occurs within 30 minutes to 1 hour.
Excretion
Approximately 80% is excreted renally as unchanged drug (about 40%) and metabolites (about 40%) within 6 days. Non-renal clearance is minimal.
Half life
Terminal elimination half-life is approximately 40 hours.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations (Cmax) achieved in approximately 5 hours. Bioavailability is about 60%.
Metabolism
Metabolized to a minor extent by multiple CYP enzymes, primarily CYP2D6 and CYP3A4, to inactive metabolites. Less than 50% is metabolized.
Side Effects
Contraindications
- •Hypersensitivity to Palonosetron or any component of the formulation.
- •Known QT prolongation or other cardiac conduction abnormalities.
Drug Interactions
0
Serotonergic drugs (e.g., SSRIs, SNRIs): Concomitant use may increase the risk of serotonin syndrome. Monitor patients for symptoms.
1
Dexamethasone: Often co-administered with palonosetron for enhanced anti-emetic effect. No significant pharmacokinetic interaction.
2
Drugs that prolong the QT interval: Caution advised with concomitant use, as palonosetron can cause dose-dependent QT prolongation.
Storage
Store below 30°C, in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
There is no known antidote for Palonosetron overdose. In case of overdose, treatment should be symptomatic and supportive. Monitor ECG and vital signs.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have not shown harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. It is not known whether palonosetron is excreted in human milk; caution advised during lactation.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24-36 months from manufacturing date
Availability
Available in pharmacies nationwide
Approval Status
Approved by regulatory authorities
Patent Status
Off-patent or patent expired
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in